AZD8701 / AstraZeneca 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD8701 / AstraZeneca
NCT04504669: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Completed
1
60
Europe, Canada, US
AZD8701, Durvalumab, MEDI4736
AstraZeneca
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD8701 / AstraZeneca
NCT04504669: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Completed
1
60
Europe, Canada, US
AZD8701, Durvalumab, MEDI4736
AstraZeneca
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
10/24
10/24

Download Options